[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659424":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":17,"collaborators":21,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":31,"eligibilityCriteria":32,"healthyVolunteers":27,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":39,"studyType":40,"phases":11,"briefSummary":41,"conditions":42,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":11},{"fullName":5,"class":6},"Amsterdam UMC, location VUmc","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The primary endpoint is the number of patients (and percentage of the total) with metastases on PSMA PET\u002FCT two years after study initiation.",null,"24 months",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","Men with histologically confirmed prostate cancer who have undergone radical prostatectomy, have experienced biochemical (PSA) recurrence, and have lymphogenic metastases in the pelvic region on PSMA PET\u002FCT.",{"type":18,"investigatorFullName":19,"investigatorTitle":20,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Prof. Dr. André N. Vis","Prof Dr.",[22],{"name":23,"class":24},"Accord Healthcare, Inc.","INDUSTRY","100659424","also-perform-study-alternating-stereotaxic-or-pelvic-radiotherapy-for-metachronic-metastatic-prostate-cancer-100659424",false,"NCT07863336","ALSO-PERFORM Study. ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer","ALSO-PERFORM Study: ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer","ALSO-PERFORM","Inclusion Criteria:\n\n* Men with histologically confirmed prostate cancer\n* Men who have undergone radical prostatectomy (RP), with or without extended pelvic lymph node dissection (ePLND)\n* Men with pNx or pN0 status in the ePLND specimen\n* Biochemical recurrence after RP (PSA \\> 0.2 ng\u002FmL on two occasions)\n* Evidence of lymphogenic metastases on staging PSMA PET\u002FCT within the pelvis (below the aortic bifurcation)\n* Life expectancy ≥ 5 years, as estimated by the treating physician\n\nExclusion Criteria:\n\n* Previous salvage radiotherapy to the prostate bed\n* Men with lymph node metastases outside the pelvis (M1a)\n* Men with osseous metastases (M1b) or visceral metastases (M1c)\n* Men with lymphogenic metastases and a local recurrence\n* Men with inguinal metastases\n* Previous treatment in the pelvic region, such as treatment of the bladder or rectum, that precludes radiotherapy to the pelvis\n* Previous treatment with an LHRH agonist\u002Fantagonist within 6 months prior to study inclusion. Patients must have normal testosterone levels (testosterone \\> 7.0 nmol\u002FL)","MALE","18 Years","99 Years",{"count":37,"type":38},130,"ESTIMATED","2 Years","OBSERVATIONAL","Outcome of metastasis directed therapy",[43],"Prostate Cancer","NOT_YET_RECRUITING","2026-10-06",{"date":47,"type":48},"2026-10-08","ACTUAL",{"date":50,"type":38},"2027-01-01",{"date":52,"type":38},"2028-12-31",{"name":5,"class":6}]